Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
Lancet Neurol. 2012 Sep;11(9):792-802. doi: 10.1016/S1474-4422(12)70153-9. Epub 2012 Jul 24.
More than 150 years after bromide was introduced as the first antiepileptic drug, adverse effects remain a leading cause of treatment failure and a major determinant of impaired health-related quality of life in people with epilepsy. Adverse effects can develop acutely or many years after starting treatment and can affect any organ or structure. In the past two decades, many efforts have been made to reduce the burden of antiepileptic drug toxicity. Several methods to screen and quantify adverse effects have been developed. Patient profiles associated with increased risk of specific adverse effects have been uncovered through advances in the areas of epidemiology and pharmacogenomics. Several new-generation antiepileptic drugs with improved tolerability profiles and reduced potential for drug interaction have been added to the therapeutic armamentarium. Overall, these advances have expanded the opportunities to tailor treatment with antiepileptic drugs, to enhance effectiveness and minimise the risk of toxic effects.
溴化物作为第一种抗癫痫药物问世 150 多年后,其不良反应仍是治疗失败的主要原因,也是影响癫痫患者健康相关生活质量的主要因素。不良反应可能在开始治疗后急性出现,也可能在多年后出现,并且可能影响任何器官或结构。在过去的二十年中,人们已经做出了许多努力来减轻抗癫痫药物毒性的负担。已经开发出了多种筛选和量化不良反应的方法。通过在流行病学和药物基因组学领域的进步,发现了与特定不良反应风险增加相关的患者特征。一些具有更好耐受性和降低药物相互作用潜力的新一代抗癫痫药物已经被加入到治疗武器库中。总的来说,这些进展扩大了用抗癫痫药物进行个体化治疗的机会,提高了治疗效果,同时降低了毒性作用的风险。